This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q77.9 (osteochondrodysplasia, unspecified) | Special Copayment Reduction: V228 (rare disease) |
| B. Synonyms | Osteochondrodysplasia with defects of growth of tubular bones and spine, unspecified |
| C. Adult onset | Likelihood of first presentation in adulthood: very low — in most osteochondrodysplasias, abnormal findings are already present at birth or in childhood. Some patients are referred when complications become evident in adulthood. |
| 1. History | History of skeletal dysplasia classification: 1970 Paris nomenclature → 2015/2023 ISDS international nomenclature of skeletal dysplasias. Q77.9 is a residual code, a provisional category expected to be reclassified into specific codes as diagnostic technology advances. |
| 2. Causes | Heterogeneous group. Skeletal dysplasias whose causative gene has not yet been identified, or cases in which no variant is found on NGS analysis. Possible abnormalities in various pathways related to endochondral ossification or cartilage matrix. |
| 3. Genetics | Various modes of inheritance (AD, AR, XL) possible. New causative genes being discovered by WES/WGS. De novo mutations in some, complex genotypes (CNV, chromosomal rearrangements) in others. |
| 4. General epidemiology | Patients classified as Q77.9 are in a provisional category of the diagnostic process. Overall prevalence of skeletal dysplasias estimated at about 1 in 5,000 births (all forms included). The proportion of Q77.9 is declining as diagnostic technology advances. |
| 5. Pathophysiology | Common mechanisms in cases of unknown cause: abnormalities of cartilage matrix synthesis, secretion and processing, abnormalities of growth plate signaling pathways (BMP, Hh, FGF, IGF, Wnt, etc.), impaired endochondral ossification. |
| 6. Symptoms | Short stature (various patterns), limb shortening or deformity, spinal abnormalities, joint dysplasia, facial abnormalities. Extent and severity vary from case to case, so there is no standard clinical picture. |
| 7. Signs | Radiological findings of skeletal dysplasia (growth plate abnormalities, epiphyseal abnormalities, abnormal tubular bone shape, spinal abnormalities) + specific diagnostic criteria for Q77.4~Q77.8 not met. Case-by-case evaluation needed. |
| 8. Screening | Skeletal abnormality suspected on prenatal ultrasound → prenatal WES/WGS. After birth, whole-skeleton radiographs → NGS panel → WES/WGS applied sequentially. Referral to a skeletal dysplasia specialist center. |
| 9. Diagnosis | Skeletal survey → skeletal dysplasia panel NGS → WES/WGS → expert review. Q77.9 is a provisional diagnosis assigned after other Q77 codes have been excluded. Reassessment needed. |
| 10. Treatment | Symptom-based multidisciplinary management. Correction of limb shortening and deformity, treatment of spinal complications, joint protection, pain management, rehabilitation. Consideration of possible targeted therapy once the cause is identified. |
| 11. Prognosis | Highly variable depending on extent and severity. Intellectual ability is often normal. Accurate diagnosis and management of complications are key to improving prognosis. |
| 12. Prevention | Genetic counseling (estimation of risk based on family history even when the cause is unknown), expert referral for abnormal prenatal findings, systematic follow-up after birth. |
| 13. References | Bonafe L et al. Am J Med Genet A 2015; Warman ML et al. Am J Med Genet A 2011; Krakow D et al. Nat Rev Genet 2021 … and 7 others |
Skeletal dysplasias are a heterogeneous group of genetic diseases characterized by abnormal development of bone and cartilage. Systematic classification of this group of diseases began in earnest in the 1960s~70s through the pioneers of the skeletal dysplasia field. In 1969, the first international consultation on skeletal dysplasia nomenclature took place in Paris and the 'Paris Nomenclature' was published, after which the classification and nomenclature system for skeletal dysplasias was periodically updated. The International Skeletal Dysplasia Society (ISDS) revised the international nomenclature of skeletal dysplasias in 2006, 2010, 2015, 2019 and 2023, and in the most recent 2019/2023 revisions, more than 460 diseases are classified into 42 groups.
The ICD-10 code Q77.9 ('osteochondrodysplasia with defects of growth of tubular bones and spine, unspecified') is a residual code assigned provisionally to patients with osteochondrodysplasia who do not fall into the specific classifications Q77.4~Q77.8, or in whom a specific diagnosis is difficult despite clinical, radiological and molecular genetic testing. This code reflects an 'undiagnosed' or 'pending classification' status, and as diagnostic technology advances, many patients classified as Q77.9 are being reclassified to specific diagnoses through next-generation sequencing (NGS) or whole exome/genome analysis (WES/WGS).
Historically, the 'unspecified' category was used because, in the era before molecular genetic diagnosis developed, an accurate diagnosis of individual patients was often impossible from clinical and radiological features alone. In the 1970s~1990s, many patients with skeletal dysplasia were placed in 'atypical' or 'unspecified' categories. However, since the 2000s, with the clinical introduction of SNP arrays, NGS panels, WES and WGS, new causative genes have been discovered rapidly, and new causative genes for skeletal dysplasias are reported every year. This progress means that the Q77.9 category is steadily shrinking.
International expert consortia (e.g., FORGE Canada, DDD UK, Deciphering Developmental Disorders) continue research to discover new causative genes in undiagnosed skeletal dysplasia patients through large-scale WES/WGS, and these efforts are contributing to improved diagnostic rates for patients in the Q77.9 category. In Korea too, rare disease diagnostic support programs and WES-based diagnostic research have expanded, and improved diagnostic rates are expected for undiagnosed skeletal dysplasia patients in Korea.
Because the Q77.9 category by definition includes osteochondrodysplasias without an identified specific cause, the description of causes takes the form of an overview of the various etiological possibilities applicable to patients in this category.
Unidentified causative gene variants: the most important reason is variants in new genes not included in the current list of known skeletal dysplasia genes. In whole exome analysis (WES), about 460 skeletal dysplasia causative genes are currently known, but the estimated total number of skeletal dysplasia genes is expected to be larger. Therefore, some patients classified as Q77.9 may have new causative genes not yet reported in the literature.
Uncertainty in variant interpretation: the diagnosis may be withheld when a variant detected on NGS analysis is a 'variant of uncertain significance (VUS)' whose clinical significance (pathogenicity) is unclear. Further evaluation of the pathogenicity of a VUS through additional functional studies, family segregation analysis and literature searches is needed.
Complex genotypes: 'complex genetics' mechanisms, in which multiple genetic factors rather than a single gene variant combine to determine the phenotype, may be involved in some skeletal dysplasias. Copy number variants (CNV), chromosomal rearrangements and epigenetic changes sometimes act as causes.
Technical limitations: standard NGS sometimes fails to detect repeat sequences, structural variants, deep intronic variants and mosaicism. Application of complementary technologies such as long-read sequencing, optical genome mapping and RNA sequencing helps detect additional variants.
The common etiological framework is that an abnormality at any stage of endochondral ossification—chondrocyte proliferation, differentiation, hypertrophy, cartilage matrix secretion, vascular invasion and bone replacement—can cause defective growth of the tubular bones and spine. The main signaling pathways involved include the FGF/FGFR, BMP/GDF, Hedgehog, Wnt, IGF, PTHrP/PTH1R and CNP/NPR2 pathways, and an abnormality in any of these pathways can be a potential cause.
The genetic background of patients in the Q77.9 category is highly heterogeneous, and various modes of inheritance and genotypes are possible. In clinical practice, when encountering a patient classified as Q77.9, efforts to reclassify the patient to a specific diagnosis through genetic evaluation should take priority.
Diversity of inheritance modes: skeletal dysplasias can show various modes of inheritance, including autosomal dominant (AD), autosomal recessive (AR), X-linked recessive (XL), X-linked dominant and mitochondrial inheritance. Assessment of family history is important for inferring the mode of inheritance. AD diseases with frequent de novo mutations can occur without a family history, and AR diseases are more common when the parents are consanguineous or from the same founder population. Analysis of family history patterns helps infer the mode of inheritance and narrow the range of candidate causative genes.
Whole exome and genome analysis: when no causative variant is identified on skeletal dysplasia panel NGS, WES (whole exome sequencing) is recommended as the next diagnostic step. WES can detect new genes in addition to known genes, and the diagnostic yield of WES in undiagnosed skeletal dysplasia patients is reported at about 20~40%. If no variant is found on WES either, WGS (whole genome sequencing) is considered; WGS can additionally detect noncoding region variants, structural variants and repeat sequence variants.
Discovery of new genes: new causative genes for skeletal dysplasias are reported every year through large-scale WES/WGS database studies and functional genomic analyses. Searching databases such as OMIM, ClinVar, LOVD and SkelDB for the latest gene-phenotype associations and sharing variant analysis results with international expert networks help resolve undiagnosed cases. Cases in which patients with variants in the same gene are found worldwide through genomic matchmaking platforms (e.g., MatchMaker Exchange, GeneMatcher) and new diseases are described are increasing.
Epigenetic and noncoding variants: in some skeletal dysplasias, variants in enhancers, promoters, noncoding RNAs and other elements that regulate gene expression may act as causes. Because such variants are not detected by standard exome analysis, further evaluation by WGS and RNA analysis is needed.
Because the Q77.9 code is an 'unspecified' category rather than a specific disease, it is difficult to give a specific frequency. However, the epidemiology of skeletal dysplasias as a whole needs to be reviewed as context for understanding this category.
The prevalence of skeletal dysplasias, all forms combined, is estimated at about 1 in 5,000 births, which shows that skeletal dysplasias are a relatively common congenital anomaly rather than a rare disease. However, the frequency of individual disease subtypes is very low, and most qualify as rare diseases. Of the more than 460 individual skeletal dysplasias included in the International Skeletal Dysplasia Society nomenclature, many are ultra-rare diseases with no more than a few hundred patients reported worldwide.
The proportion of patients classified as Q77.9 varies greatly with the level of diagnostic technology. Before molecular genetic diagnosis became widespread, a considerable number of skeletal dysplasia patients were placed in 'unspecified' or 'other' categories. Currently, applying NGS panels and WES at skeletal dysplasia specialist centers allows a molecular genetic diagnosis in about 50~70% of patients. The remaining 30~50% cannot be diagnosed with current technology and knowledge and are assigned an 'unspecified' code such as Q77.9.
In Korea, undiagnosed skeletal dysplasia patients can receive rare disease benefits through Special Copayment Reduction (V228) and can receive diagnostic support services through the Rare Disease Helpline and Korean rare disease specialist centers (National Medical Center, rare disease centers at university hospitals). Data on skeletal dysplasia patients registered in the Korean rare disease registry system (NRDR) are being used for epidemiological research.
The specific pathogenesis in patients in the Q77.9 category differs from case to case, and when the causative gene has not been identified, it is difficult to describe the exact mechanism. However, the common pathological processes that cause defective growth of the tubular bones and spine can be outlined.
Abnormalities of endochondral ossification: growth of the long bones and spine depends on endochondral ossification at the growth plate. This process includes the stages of ① differentiation of chondroprogenitors into chondrocytes, ② cell division and column formation of proliferating chondrocytes, ③ differentiation into hypertrophic chondrocytes and secretion of cartilage matrix, ④ vascular invasion and influx of osteoblasts, ⑤ replacement of cartilage matrix by bone matrix and ⑥ bone remodeling by osteoclasts. An abnormality at any stage of this complex process impairs the longitudinal growth of bone.
Major signaling pathways: the major signaling pathways regulating endochondral ossification are ① FGF/FGFR: FGFR3 hyperactivation (achondroplasia) is the best-known example, but other FGF receptors and ligands are also involved in chondrocyte growth. ② BMP/GDF: regulates chondrocyte differentiation and joint formation. ③ Hedgehog (IHH/SHH): maintains proliferating chondrocytes in the growth plate and regulates hypertrophy through the PTHrP loop. ④ Wnt/β-catenin: regulates the transition from chondrocytes to osteoblasts. ⑤ IGF-1: promotes chondrocyte proliferation as a downstream signal of growth hormone. ⑥ PTHrP (PTH1R): regulates the rate of hypertrophy. ⑦ CNP/NPR2: promotes chondrocyte growth through MAPK inhibition. Dysfunction in any gene of these pathways can cause defective growth of the tubular bones and spine.
Abnormalities of cartilage matrix: variants in genes encoding components of the cartilage matrix, such as type II collagen (COL2A1), cartilage oligomeric matrix protein (COMP), aggrecan (ACAN) and chondroitin sulfate synthases, also cause various skeletal dysplasias. Abnormalities of matrix components impair both structural support and growth factor binding functions.
Common features of molecular mechanisms: even though the causative genes vary, when the growth plate microenvironment that ensures proper chondrocyte proliferation and differentiation is damaged, the result converges on tubular bone growth plate dysfunction and abnormal vertebral body development. This is why the diseases of the Q77 code group, including Q77.9, are commonly characterized by 'defects of growth of tubular bones and spine.'
Because the symptoms of patients in the Q77.9 category by definition do not fully match the typical findings of a specific subtype and are therefore classified as 'unspecified,' there is no standard clinical picture. Patients in this category commonly show defective growth of the tubular bones and spine, the general feature of osteochondrodysplasias, but the specific features vary greatly between individuals.
Skeletal symptoms: short stature appears in most patients, and the pattern of limb shortening (rhizomelic, mesomelic, acromelic or mixed) varies by subtype. Spinal abnormalities (platyspondyly, scoliosis, kyphosis) accompany it to varying degrees. Joint dysplasia, joint contractures and joint deformities may occur. When there is thoracic narrowing, there is a risk of respiratory failure in infancy. Osteoporosis or osteosclerosis may accompany some subtypes.
Craniofacial symptoms: some patients may have abnormal skull shape (macrocephaly, microcephaly, craniosynostosis), facial skeletal abnormalities and hearing loss. When there are skull base abnormalities, neurological complications may accompany them.
Extraskeletal symptoms: depending on the individual case, various extraskeletal symptoms such as ophthalmological abnormalities (myopia, retinal abnormalities), hearing loss, cardiovascular abnormalities, renal abnormalities and skin abnormalities may accompany it. Because these extraskeletal abnormalities can be clinical clues to specific subtypes, systematic checking is needed.
Intellectual development: in most osteochondrodysplasias intellectual ability is normal, but intellectual disability may accompany some complex syndromes. Assessment of intellectual ability can provide an important clue for differential diagnosis.
Assessment of signs in patients in the Q77.9 category has the following goals: ① confirming that it is a skeletal dysplasia, ② confirming that it does not meet the specific diagnostic criteria for Q77.4~Q77.8, ③ identifying any complications and ④ obtaining baseline data for later diagnostic review.
Physical signs: height (compared with age-specific standards), weight, body proportions (sitting height/standing height ratio, arm span/height ratio), head circumference, characteristic facial features, limb shortening pattern, abnormal spinal curvature (inspection and palpation), joint range of motion and skin/nail abnormalities are assessed systematically. Neurological examination assesses signs of cervical or lumbar cord compression (strength, reflexes, sensation, bladder function).
Radiological signs: a skeletal survey is central to the diagnosis and includes all the standard views: skull (AP and lateral), chest, spine (AP and lateral), pelvis and upper and lower limbs (AP). Growth plate abnormalities (width, density), delayed or irregular epiphyseal ossification, tubular bone shape, vertebral body shape, bone density, cortical thickness, joint spaces and so on are assessed. A diagnosis of Q77.9 is considered when the radiological findings do not fully match any of the existing named skeletal dysplasias.
Follow-up radiographs: in growing patients, radiographs are repeated at 1~2-year intervals to follow growth plate changes and the progression of skeletal abnormalities. In some skeletal dysplasias, radiological findings change with growth, so the condition may later be classified as a specific diagnosis.
A stepwise diagnostic approach is recommended for undiagnosed skeletal dysplasias, including patients in the Q77.9 category.
Prenatal ultrasound: when skeletal abnormalities (limb shortening, thoracic narrowing, craniofacial abnormalities) are seen on standard prenatal ultrasound, detailed fetal ultrasound and genetic analysis are requested immediately. The search for causative genes of fetal skeletal dysplasias using prenatal WES/WGS has recently been expanding gradually in clinical practice. Distinguishing lethal skeletal dysplasias (e.g., thanatophoric dysplasia) from nonlethal forms is important for birth decisions and preparation for delivery.
Postnatal clinical screening: when a skeletal dysplasia is suspected at birth, a skeletal survey is performed immediately and review by a skeletal dysplasia specialist is requested. At the same time, metabolic bone diseases are excluded with blood tests (calcium, phosphorus, alkaline phosphatase, thyroid hormones, etc.).
Stepwise molecular genetic approach: ① targeted analysis of specific genes based on clinical findings (e.g., FGFR3 analysis first when achondroplasia is suspected). ② When differential diagnosis is difficult, an NGS-based skeletal dysplasia gene panel (50~200 genes). ③ If no variant is found on the panel, whole exome sequencing (WES). ④ If none is found on WES either, whole genome sequencing (WGS) and RNA analysis. ⑤ Sharing the case with skeletal dysplasia specialist centers and undiagnosed rare disease networks in Korea and abroad.
The Q77.9 diagnosis is a process of active diagnostic exclusion. That is, it is a provisional code assigned when the condition does not correspond to a specific diagnosis even after every available diagnostic means has been used in an attempt to reach a specific diagnosis.
Step 1 — clinical and radiological evaluation: detailed history (birth history, developmental history, family history, history of bleeding, infection or drug exposure), full physical examination and skeletal survey. Experts review the radiological features of the skeletal dysplasia to first check whether it corresponds to a specific diagnostic code (Q77.4~Q77.8, or another skeletal dysplasia code outside Q77). Collaboration with skeletal dysplasia specialists (medical genetics, pediatrics, orthopedics) or radiology experts is important.
Step 2 — molecular genetic analysis: targeted gene analysis according to clinical findings or an NGS skeletal dysplasia panel. If a causative variant is identified at this step, the condition is reclassified to a specific diagnosis. If no variant is identified, WES follows.
Step 3 — WES/WGS analysis: WES or WGS detects new variants outside known genes. Parent trio analysis (simultaneous WES of the patient and parents) is effective for detecting de novo mutations and assessing variant pathogenicity. If no variant is identified at this step either, the Q77.9 diagnosis is provisionally maintained, and reassessment is planned as technology advances.
Principles of differential diagnosis: before assigning Q77.9, it is necessary to exclude Q77.4 (achondroplasia), Q77.5 (diastrophic dysplasia), Q77.6 (Ellis-van Creveld), Q77.7 (spondyloepiphyseal dysplasia) and Q77.8 (other osteochondrodysplasias), as well as skeletal dysplasias outside the other Q77 codes (e.g., chondrodysplasia punctata Q77.3, hypochondroplasia, etc.) and non-genetic skeletal abnormalities (rickets, osteomalacia, bone marrow diseases).
Treatment of patients classified as Q77.9 follows the principle of symptomatic multidisciplinary management based on individual clinical problems and complications. Even when the cause is unidentified, active treatment to relieve symptoms and improve function should be provided.
Respiratory management: when there is thoracic narrowing, mechanical ventilatory support may be needed in infancy. If there is sleep apnea, positive airway pressure (CPAP) therapy or upper airway surgery is considered after polysomnography.
Management of neurological complications: when cervical instability is confirmed, prophylactic immobilization, activity restriction and, if necessary, surgical decompression and fusion are performed. When there is foramen magnum stenosis, neurosurgical decompression is considered. If there are neurological symptoms due to spinal stenosis, surgical decompression is decided on after conservative treatment.
Joint and limb treatment: when limb deformity affects walking or function, osteotomy, limb lengthening and corrective joint surgery are considered. If early degenerative arthritis due to joint dysplasia progresses, pain management and ultimately joint replacement are considered. Physical therapy and occupational therapy maximize functional independence.
Spinal treatment: depending on the degree of scoliosis and kyphosis, bracing or surgical correction is performed. Spinal surgery is performed by a spine surgery team experienced with skeletal dysplasia patients.
Targeted therapy after identification of the cause: if the causative gene is later identified through molecular genetic analysis, the applicability of targeted therapy for the signaling pathway to which the gene variant belongs (e.g., vosoritide in FGFR3-related cases, methods of increasing cGMP in NPR2-related cases) is reviewed. Therefore, it is important to keep pursuing a diagnosis while following the latest developments in therapeutics.
Psychosocial support: considering the psychological burden on patients and families living without an accurate diagnosis, linkage with genetic counselors, psychological professionals and patient organizations (such as support groups for undiagnosed rare disease patients) is supported.
The prognosis of patients in the Q77.9 category varies greatly depending on the affected skeletal regions, the presence and severity of complications and access to treatment. It is difficult to generalize a specific prognosis, but the following general prognostic framework applies.
Life expectancy: when fatal neonatal complications (respiratory failure, central nervous system complications) are managed, life expectancy in most nonlethal osteochondrodysplasias is close to normal. However, life expectancy may be affected when severe thoracic narrowing, central nervous system complications or cardiac malformations are present. For accurate prognostic prediction, it is important to reach a specific diagnosis whenever possible.
Functional prognosis: walking ability, hand function and independence in daily living are determined by the severity of limb shortening and joint abnormalities. Physical therapy, orthoses and surgical correction improve the functional prognosis. Intellectual ability is mostly normal, and education and employment are possible.
Chronic pain and quality of life: chronic pain due to joint dysplasia, early degenerative arthritis and spinal complications has a major impact on quality of life. Regular pain assessment and management and rehabilitation are essential for maintaining quality of life.
Importance of diagnosis: identification of the causative gene contributes directly to improved prognosis in terms of ① predicting complications and preventive management, ② appropriate genetic counseling, ③ access to future targeted therapies and ④ providing opportunities to participate in clinical trials. Therefore, continuing efforts to pursue a diagnosis even after the Q77.9 code has been assigned is recommended.
Genetic counseling when the cause is unidentified: even when the causative gene has not been identified, the mode of inheritance can be inferred from analysis of family history patterns, and recurrence risk can be counseled on that basis. If siblings of an affected patient have similar symptoms, the possibility of the same diagnosis is considered, and parental analysis (quartet or trio) increases the chance of detecting the causative variant. If there are family members with a similar phenotype, they should also be evaluated systematically.
Prenatal management: when a skeletal dysplasia has occurred in a previous child, detailed prenatal ultrasound (18~22 weeks of gestation) and molecular genetic analysis (prenatal diagnosis if the causative variant is known, prenatal WES if not) are performed in the next pregnancy. If an affected fetus is identified by prenatal diagnosis, a multidisciplinary team establishes a delivery plan before birth and prepares a system for immediate neonatal evaluation and treatment.
Regular follow-up to prevent complications: for patients provisionally diagnosed with Q77.9, complication risk is assessed according to the underlying clinical findings, and a schedule of regular tests appropriate to the risk factors is established. If there is a risk of cervical instability, cervical spine MRI is performed regularly and education on activity restriction is provided. If there are ophthalmological abnormalities, regular eye examinations are performed, and if sleep apnea is suspected, polysomnography is performed.
Participation in rare disease networks: patients are registered in the Korean rare disease registry program (NRDR), and cases are shared with international undiagnosed rare disease research networks (e.g., the Undiagnosed Diseases Network, UDN) to increase the chance of discovering the causative gene. Through this, patients with the same or similar phenotypes are identified, and patients participate in collaborative research describing new diseases.
Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869-2892. DOI: 10.1002/ajmg.a.37365. PMID: 26394607.
Warman ML, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011;155A(5):943-968. DOI: 10.1002/ajmg.a.33909. PMID: 21438135.
Krakow D, Lachman RS, Rimoin DL. Guidelines for the prenatal diagnosis of fetal skeletal dysplasias. Genet Med. 2009;11(2):127-133. DOI: 10.1097/GIM.0b013e3181971ccb. PMID: 19197162.
Unger S, Ferreira CR, Mortier GR, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164-1209. DOI: 10.1002/ajmg.a.63132. PMID: 36779427.
Nampoothiri S, Yesodharan D, Sainulabdin G, et al. Spectrum and outcome of rare genetic skeletal disorders in a pediatric hospital in India. Am J Med Genet A. 2014;164A(5):1143-1153. DOI: 10.1002/ajmg.a.36421. PMID: 24478135.
Superti-Furga A, Unger S. Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A. 2007;143A(1):1-18. DOI: 10.1002/ajmg.a.31528. PMID: 17120254.
Bober MB, Bellus GA, Nikkel SM, et al. Hypochondroplasia — Gene Reviews. NCBI Bookshelf. 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1477/
Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312(18):1880-1887. DOI: 10.1001/jama.2014.14604. PMID: 25326637.
Boycott KM, Rath A, Chong JX, et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am J Hum Genet. 2017;100(5):695-705. DOI: 10.1016/j.ajhg.2017.04.003. PMID: 28475858.
Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med. 2013;369(16):1502-1511. DOI: 10.1056/NEJMoa1306555. PMID: 24088041.